Vildagliptin Effective across Hyperglycemia Spectrum
{"Image DocumentName": "Vildagliptin Effective across Hyperglycemia Spectrum", "Image ImageDescription": "Overall. BL HbA1c \u22648% 8< HbA1c \u22649% 9< HbA1c \u226410% HbA1c >10% n= BL=   Change from BL in HbA1c (%)     Vildagliptin: Effective across Hyperglycemia Spectrum. Pooled Analysis in Monotherapy 50 mg Twice Daily. Data from four trials were pooled to assess the effect of vildagliptin 50 mg twice daily on HbA1c. All trials were double-blind, randomized, multicenter, parallel-group studies. Three trials lasted for 24 weeks; the fourth trial lasted for 52 weeks. Changes from baseline in HbA1c at 24 weeks for five patient groups were analyzed: 1) the pooled population overall (n=1569) 2) patients with baseline HbA1c \u22648% (n=543) 3) patients with baseline HbA1c >8% to \u22649% (n=490) 4) patients with baseline HbA1c >9% to \u226410% (n=362) 5) patients with baseline HbA1c >10% (n=174) Significant changes from baseline of \uf02d1.0%, \uf02d0.6%, \uf02d0.9%, \uf02d1.6%, and \uf02d1.9% were obtained for the overall, HbA1c \u22648%, HbA1c >8% to \u22649%, HbA1c >9% to \u226410%, and HbA1c >10% patient populations, respectively. These data demonstrate that vildagliptin is an effective glucose-lowering agent, offering glycemic control across a wide spectrum of patients with hyperglycemia. Reference. Summary of Clinical Efficacy, 13 September Tables 2-1.5d1, 2-1.5d3. Novartis Pharmaceuticals.     Vilda 50 mg twice daily. BL=baseline; HbA1c-hemoglobin A1c; vilda=vildagliptin  P <0.001 from BL. HbA1c change from baseline to Week 24 (end point) pooled monotherapy intention-to-treat / primary intention-to-treat population. Data on file, Novartis Pharmaceuticals.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}